Neogen (NEOG) Q3 2025: Tariff Exposure Hits $30M Run Rate as Macro Weakness Forces Guide Down
Neogen’s Q3 revealed a decisive macro-driven slowdown, compounded by fresh tariff exposure and CEO transition risk. Management is moving to realign costs and sharpen portfolio focus, but softening demand and integration drag remain material headwinds. Investors face a dynamic landscape as Neogen works to stabilize execution and restore growth momentum into FY26.
Summary
- Macro Drag Intensifies: Uncertainty and tariff actions drove a pronounced pullback in distributor inventory and customer ordering.
- Integration and Portfolio Actions Accelerate: Management is restructuring genomics, refocusing on food safety, and targeting cost reductions to match new revenue realities.
- FY26 Hinges on Execution: Restoring sample collection, de-risking PetriFilm, and managing tariff fallout are critical levers for recovery.
Performance Analysis
Neogen’s Q3 core revenue growth was essentially flat, as macro uncertainty and tariff dynamics pressured both the food safety and animal safety segments. Food safety revenue, the company’s largest business, declined 3.2% YoY, with core growth of only 1.5% after FX headwinds and ongoing sample collection disruption. Excluding sample collection, core food safety grew 7%, but this was still below management’s expectations given softening late-quarter demand.
Animal safety core revenue fell 2.6% YoY, with pronounced weakness in China and continued distributor caution globally. Genomics remained a drag, down mid-single digits, though the differentiated bovine business showed resilience. Gross margin compressed 120 bps YoY, reflecting lower volumes and integration costs, while free cash flow improved sequentially but remained negative. The updated full-year guide reflects these persistent headwinds, with management highlighting $30M in run-rate tariff exposure—two-thirds tied to China—and further cost actions planned for Q4.
- Distributor Hesitancy: Both domestic and international partners pulled back on inventory, reflecting uncertainty around tariffs and food production.
- Genomics Reset: Restructuring continues, with focus shifting to core bovine offerings as non-core lines wind down.
- Integration Still in Progress: Sample collection production is restored, but PetriFilm transition remains a multi-quarter risk with duplicative costs expected in FY26.
Execution against these headwinds will define the company’s near-term trajectory, as management seeks to align costs and portfolio to a more muted demand environment.
Executive Commentary
"Over the course of the third quarter, we saw the broad development of uncertainty, primarily related to the goals and policies of the U.S. government, most notably deregulation, government spending cuts, tariffs, and global trade... We believe that uncertainty increased as the quarter progressed and read through to our end markets, which contributed to our third quarter results being below our expectations."
John Avent, Chief Executive Officer
"Our third quarter revenues were $221 million... Core revenue growth... came in at 20 basis points for the quarter, while foreign currency was a headwind of 310 basis points compared to the prior year. Gross margin in the third quarter was 49.9%, representing a decrease of 120 basis points from 51.1% in the same quarter a year ago."
Dave Namura, Chief Financial Officer and Chief Operating Officer
Strategic Positioning
1. Tariff Volatility and Market Exposure
Tariffs have emerged as a material risk, with management quantifying a potential $30M annualized impact—two-thirds tied to China—before mitigation. While only 2.5% of revenue is generated in China, the animal safety segment is disproportionately exposed to tariff-driven COGS (cost of goods sold) increases. Pricing power and local manufacturing are partial offsets, but volume and margin risk remain high as global trade dynamics evolve.
2. Food Safety: Resilient but Slowing
Food safety remains Neogen’s core franchise, but even this historically stable market is showing cracks. Excluding sample collection, core food safety grew 7%, but management had expected double-digit growth. Late-quarter demand softness and distributor caution signal that food safety, while durable, is not immune to macro shocks.
3. Genomics Restructuring and Portfolio Pruning
Neogen is actively winding down non-core genomics offerings, concentrating on its differentiated bovine business (estimated at $50M+ annual run rate). This shift is expected to be margin accretive and free up resources for debt paydown, but also means near-term revenue headwinds as legacy lines are exited.
4. Integration Execution and Cost Realignment
The long-running integration of the 3M Food Safety acquisition is nearing completion, with PetriFilm production transition the last major hurdle. Management anticipates temporary duplicative costs in FY26 as SKUs are moved in phases. Concurrently, cost actions are underway to right-size the expense base for a lower revenue environment, with further reductions planned for Q4.
5. Leadership Transition and Commercial Focus
CEO John Avent’s impending departure adds leadership uncertainty at a critical juncture. However, the company has refreshed its R&D and commercial leadership, and is prioritizing demand generation and customer engagement in North America. The search for a Chief Commercial Officer is ongoing, with a Q1 FY26 target fill.
Key Considerations
Neogen’s Q3 marks a strategic inflection, with management forced to confront both external volatility and internal execution gaps. The next twelve months hinge on the following:
Key Considerations:
- Tariff and Trade Risk Management: The $30M run-rate tariff exposure, especially in animal safety, will test pricing power and supply chain agility.
- Sample Collection Recovery: Production is restored, but revenue normalization and backorder reduction are essential to reignite growth.
- PetriFilm Transition: The phased shift to in-house production introduces duplicative costs and operational risk through FY26.
- Cost Realignment: Management is acting to better match expenses to a lower revenue base, but successful execution is required to protect margins.
- Leadership Continuity: The CEO transition and pending CCO hire are pivotal for commercial momentum and strategic clarity.
Risks
Material risks include escalating tariffs, especially if global trade tensions worsen or mitigation actions lag. Execution risk is elevated as portfolio pruning, integration, and cost cuts converge with a CEO transition. Food safety demand, while resilient, is now visibly sensitive to macro shocks, and animal safety remains in a cyclical trough. FX volatility and persistent inflation add further unpredictability to near-term results.
Forward Outlook
For Q4, Neogen guided to:
- Continued macro-driven demand softness and cautious distributor behavior
- Initial financial impact from new tariff actions
For full-year 2025, management lowered guidance to:
- Revenue of approximately $895 million
- Adjusted EBITDA of approximately $195 million
- Free cash flow outflow of ~$20 million (reflecting higher CapEx and lower EBITDA)
Management is focused on cost containment, working capital reduction, and restoring growth in sample collection and food safety. Portfolio actions and further cost alignment are expected to be visible in FY26.
Takeaways
Neogen’s Q3 underscores the vulnerability of even resilient end markets to macro and trade shocks. The company is proactively restructuring and realigning, but the path to normalized growth and margin remains multi-quarter.
- Tariff Impact Is Real: $30M in run-rate exposure, especially in animal safety, will pressure both margin and volume until mitigation takes hold.
- Portfolio and Cost Actions Are Accelerating: Genomics restructuring, cost cuts, and focused capital allocation are necessary responses to a new revenue baseline.
- FY26 Will Be a Test of Execution: Investors should watch for progress on PetriFilm, sample collection, and leadership stability as signals of a sustainable turnaround.
Conclusion
Neogen’s Q3 results reflect a company at a crossroads, facing external volatility and internal transformation. The next year will test management’s ability to execute on integration, cost realignment, and commercial revitalization, all while navigating leadership change and tariff uncertainty.
Industry Read-Through
Neogen’s results signal that food and animal safety testing, while historically resilient, are no longer immune to macro and trade volatility. The pronounced pullback in distributor inventory and customer ordering may foreshadow similar caution across diagnostics and agtech peers. Tariff risk and supply chain localization are rising themes for all global life sciences and food safety businesses. Investors should expect continued volatility in end-market demand and margin structure as regulatory and trade environments remain fluid.